Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat + Ruxolitinib in Myelofibrosis
NCT03386214Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pevonedistat in myelofibrosis (MF), sponsored by Washington University School of Medicine. Primary endpoints: Frequency of adverse events and Maximum Tolerated Dose. Started Apr 2018; status: terminated.
02
Drugs
pevonedistat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03386214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386214.